Tharimmune Announces Phase 2 Study Plan for TH104 in Patients With Moderate-to-Severe Pruritus Associated With Primary Biliary Cholangitis and Provides a Business Update
Portfolio Pulse from
Tharimmune, Inc. (Nasdaq:THAR) announced plans for a Phase 2 study of TH104 for treating pruritus in primary biliary cholangitis patients, following positive Phase 1 results and regulatory feedback.
December 16, 2024 | 1:15 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Tharimmune plans to start a Phase 2 study for TH104 in 2025, targeting pruritus in PBC patients. This follows positive Phase 1 results and regulatory feedback, indicating potential progress in their drug development pipeline.
The announcement of a Phase 2 study for TH104 suggests progress in Tharimmune's drug development, which is likely to be viewed positively by investors. The positive Phase 1 results and regulatory feedback further support this outlook, potentially boosting investor confidence and the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100